View Filing Data

Goodwill and Intangible Assets Disclosure [Abstract]

WEB DEVELOPMENT COSTS

The Company has capitalized costs in developing their website and web-based products, which consisted of the following as of September 30, 2013 and December 31, 2012:

	2013			2012
OptimizeRx web development	$	154,133		$	154,133
SampleMD web development		602,517			602,517
SampleMD 2.0		62,280			0
Subtotal, web development costs		818,930			756,650
Accumulated amortization		(408,069	)		(310,352	)
Impairment		(59,083	)		(59,083	)
Web development costs, net	$	351,778		$	387,215

Amortization is recorded using the straight-line method over a period of five years. The Company is currently developing an enhanced SampleMD website and has capitalized $62,280. The development is currently in process. It is not completed at September 30, 2013. Accordingly, no amortization has been recorded. The development is expected to be completed in 2014. The Company determined that the original OptimizeRx website was no longer useful so the remaining unamortized balance of $59,083 was impaired as of December 31, 2010. Amortization expense for the web development costs was $32,572 and $31,677 for the three months ended September 30, 2013 and 2012, respectively. Amortization expense for the web development costs was $97,717 and $94,964 for the nine months ended September 30, 2013 and 2012, respectively.

PATENT RIGHTS AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2013

PATENT RIGHTS AND INTANGIBLE ASSETS

On April 26, 2010, the Company acquired from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for the SampleMD patent currently in process in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to 200,000 stock options valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.

The Company has capitalized costs in purchasing and defending the SampleMD patent, which consisted of the following as of September 30, 2013 and December 31, 2012:

	2013			2012
Patent rights and intangible assets	$	930,000		$	930,000
Patent defense costs		38,278			0
Accumulated amortization		(179,388	)		(136,764	)
Patent rights and intangible assets, net	$	788,890		$	793,236

The Company began amortizing the patent, using the straight-line method over the estimated useful life of 17 years, once it was put into service in July 2010. In 2013, the Company began incurring costs related to defense of the patent. These costs have been capitalized and will be amortized using the straight-line method over the remaining useful life of the original patent. Amortization expense was $14,246 and $13,676 for the three months ended September 30, 2013 and 2012, respectively. Amortization expense was $42,624 and $41,029 for the nine months ended September 30, 2013 and 2012, respectively.

ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2013

Payables and Accruals [Abstract]

ACCRUED EXPENSES

On January 14, 2013, the Company hired a new CEO. The employment agreement required annual compensation of $175,000 that was to be accrued and deferred until at least January 1, 2014. Additionally, the agreement required the issuance of 2,000,000 options with an exercise price of $1.00 for a term of five years. The options were not exercisable until at least January 1, 2014. On September 20, 2013, the Company entered into a separation agreement with the CEO. As part of the agreement, the accrued compensation was paid through the date of separation and the options were terminated.

Accrued expenses consisted of the following as of September 30, 2013 and December 31, 2012:

	2013		2012
Accrued compensation	$	0	$	0
Accrued audit fees		0		6,000
Total accrued expenses	$	0	$	6,000

DEFERRED REVENUE	9 Months Ended
DEFERRED REVENUE	Sep. 30, 2013
Revenue Recognition [Abstract]
DEFERRED REVENUE	The Company has signed several contracts with customers for either the distribution or redemption of coupons. The payments are not taken into revenue until either the coupon is distributed to a patient or the coupon has been redeemed depending on the specific contract. The distributions and redemptions are tracked by the Company’s administrative tool. Additionally, customer setup contracts that have been paid in full are deferred until the Company has completed the obligations of the contacts. Deferred revenue was $13,272 and $49,252 as of September 30, 2013 and December 31, 2012, respectively.

RELATED PARTY TRANSACTIONS	9 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2013
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	During the year ended December 31, 2010, the Company acquired from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for the SampleMD patent currently in process in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to 200,000 stock options valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

COMMON STOCK

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

COMMON STOCK

OptimizeRx Corporation has 500,000,000 shares of $.001 par value common stock authorized as of September 30, 2013.

There were 14,752,496 and 14,232,496 common shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively.

On June 1, 2012, the Company entered into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 40,000 shares of common stock as of the date of the contract. However, these shares were not issued until July 12, 2012. The Company also agreed to issue an additional 40,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement. The first 40,000 shares were valued at the Company’s common stock price as of the date of the contract, which was $1.12/share and has been expensed. No additional shares were issued and the agreement was voided and replaced by a new agreement as noted below.

On June 1, 2013, the Company entered into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 20,000 shares of common stock as of the date of the contract. The Company also agreed to issue an additional 20,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement. The first 20,000 shares were valued at the Company’s common stock price as of the date of the contract, which was $1.945/share and has been expensed.

On September 20, 2013, the Company entered into a separation agreement that includes post-employment consulting services with a former officer. The Company agreed to issue 500,000 shares of common stock, 250,000 shares immediately and 250,000 by January 1, 2014. The first 250,000 shares have been issued and the Company has recognized the entire issuance in the September 30, 2013 shares outstanding. The shares were valued at $505,000 and $233,077 of that amount has been recorded as deferred stock compensation as of September 30, 2013.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

PREFERRED STOCK

9 Months Ended

Sep. 30, 2013

Equity [Abstract]

PREFERRED STOCK

Series A Preferred

During the year ended December 31, 2008, 35 preferred shares were issued for $3,500,000. Issuance costs totaled $515,000 resulting in net proceeds of $2,985,000. The 35 shares are convertible to 3,500,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 6,000,000 shares of common stock at an exercise price of $2 for a period of seven years.

Series A Preferred Continued

The holders of the preferred stock are entitled to semi-annual dividends payable on the stated value of the Series A preferred stock at a rate of 10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series A preferred stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1 conversion price.

On May 12, 2010, the Company’s Board declared and issued 236,598 common shares as payment for all cumulative and current semi-annual dividends. On November 16, 2010, the Company’s Board declared and issued 173,922 common shares for its semi-annual dividend payment. On March 25, 2011, the Company’s Board declared and issued 176,768 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 156,306 common shares for its semi-annual dividend payment. The Company has undeclared dividends that were due in February and September 2012 totaling $350,000 and undeclared dividends of $350,000 that were due in February and September 2013 for a total undeclared amount of $700,000 as of September 30, 2013.

Series B Preferred

During the year ended December 31, 2010, 15 preferred shares were issued for $1,500,000. The 15 shares are convertible to 1,000,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 3,000,000 shares of common stock at an exercise price of $3 for a period of seven years.

The preferred stock was issued for $1,500,000 less associated issuance costs of $350,000 for net proceeds of $1,150,000. Additionally, 3,000,000 common stock warrants were issued with the preferred stock. Based on the fair values of the preferred stock and common stock warrants on the issue date, $341,100 was allocated to preferred stock and $1,158,900 was allocated to the common stock warrants. Equity issuance costs of $350,000 were allocated to the preferred stock.

During the quarter ended September 30, 2011, 15 preferred shares were issued to an investor for $1,500,000. The 15 shares are convertible to 1,000,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 1,000,000 shares of common stock at an exercise price of $3 for a period of seven years. Based on the fair values of the preferred stock and common stock warrants on the issue date, $855,460 was allocated to preferred stock and $644,540 was allocated to the common stock warrants. See Note 12.

Series B Preferred Continued

The holders of the preferred stock are entitled to semi-annual dividends payable on the stated value of the Series B preferred stock at a rate of 10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series B preferred stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1.50 conversion price.

The holder may cause this conversion at the time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided, at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. On March 25, 2011, the Company’s Board declared and issued 75,758 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 66,988 common shares for its semi-annual dividend payment. The Company has undeclared dividends that were due in February and September 2012 totaling $150,000 and undeclared dividends of $150,000 that were due in February and September 2013 for a total undeclared amount of $300,000 as of September 30, 2013.

STOCK OPTIONS AND WARRANTS

9 Months Ended

Sep. 30, 2013

STOCK OPTIONS AND WARRANTS

The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values.

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered.

On May 31, 2011, the Company issued 285,000 stock options to 3 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 218%, risk-free interest rate of 1.68% and expected life of 60 months. The total value of the options was $320,585. The options vest over one year. The Company recognized share-based compensation expense of $187,005 during the year ended December 31, 2011. The remaining balance of $133,580 was recognized over the first five months of 2012.

During the quarter ended December 31, 2011, the Company issued 20,000 stock options to 2 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 204-205%, risk-free interest rate of 0.88-0.93% and expected life of 60 months. The total value of the options was $19,270. The options vest over one year. The Company recognized share-based compensation expense of $2,480 during the year ended December 31, 2011 and $14,459 during the nine months ended September 30, 2012. The remaining balance was recognized during the remainder of 2012.

On November 21, 2011, the Company issued 100,000 stock options to an individual at an exercise price of $0.73. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 205%, risk-free interest rate of 0.92% and expected life of 60 months. The Company recognized expenses of $8,346 during the year ended December 31, 2011 and $75,117 during the nine months ended September 30, 2012. The remaining balance was recognized during the remainder of 2012.

During the quarter ended March 31, 2012, the Company issued 50,000 stock options to 4 non-employees at an exercise price of $0.89. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 198%, risk-free interest rate of 0.65% and expected life of 48 months. The total value of the options was $35,091. The options vest over 4 months. The Company recognized share-based compensation expense of $35,091 during the six months ended June 30, 2012.

During the quarter ended December 31, 2012, the Company issued 25,000 stock options to a non-employee at an exercise price of $1.58. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 200%, risk-free interest rate of 0.67% and expected life of 60 months. The total value of the options was $40,007. The options vest over 1 year. The Company recognized share-based compensation expense of $8,335 during the three months ended December 31, 2012 and $30,006 during the nine months ended September 30, 2013. The remaining balance will be recognized over the remainder of 2013.

The Company had the following options outstanding as of September 30, 2013:

	Number of Options			Weighted average exercise price
Outstanding, January 1, 2012		405,000		$	1.01
Granted - 2012		75,000			1.17
Exercised - 2012		0			0
Expired - 2012		(455,000	)		(.98	)
Balance, December 31, 2012		25,000			1.58
Granted - 2013		0			0
Exercised - 2013		0			0
Expired - 2013		0			0
Balance, September 30, 2013		25,000		$	1.58

The Company had the following warrants outstanding as of September 30, 2013:

	Number of Warrants			Weighted average exercise price
Outstanding, January 1, 2012		14,344,434		$	2.41
Granted - 2012		0			0
Exercised - 2012		0			0
Expired - 2012		0			0
Balance, December 31, 2012		14,344,434			2.41
Granted - 2013		0			0
Exercised - 2013		0			0
Expired - 2013		(672,000	)		(2.59	)
Balance, September 30, 2013		13,672,434		$	2.44

OPERATING LEASES

9 Months Ended

Sep. 30, 2013

Leases [Abstract]

OPERATING LEASES

The Company signed a lease for new office space on December 1, 2011 at an approximate rent of $5,000 per month. The new offices are in Rochester, Michigan. The lease is for three years with an option to renew for an additional two years at approximately $5,200 per month with six months advance notice to exercise the option. Minimum annual rent is as follows for the initial term of the lease:

Year ended December 31, 2013	$	60,591
2014		55,542
2015		0
Total lease commitment	$	116,133

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

MAJOR CUSTOMERS	9 Months Ended
MAJOR CUSTOMERS	Sep. 30, 2013
Notes to Financial Statements
MAJOR CUSTOMERS	The Company had three major customers that accounted for 68% and two major customers that accounted for 50% of the Company’s revenues for the nine months ended September 30, 2013 and 2012, respectively. The Company expects to continue to maintain these relationships with the customers.

INCOME TAXES

9 Months Ended

Sep. 30, 2013

Income Tax Disclosure [Abstract]

INCOME TAXES

For the nine months ended September 30, 2013, the Company incurred net income of approximately $260,000 but has no tax liability. The Company began operations in 2007 and has previous net operating loss carry-forwards of approximately $13,843,000 through December 31, 2012. The cumulative loss of approximately $13,583,000 will be carried forward and can be used through the year 2033 to offset future taxable income. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting.

The provision for Federal income tax consists of the following for the nine months ended September 30, 2013 and 2012:

	2013			2012
Federal income tax (expense) benefit attributable to:
Current operations	$	(88,000	)	$	102,000
Valuation allowance		88,000			(102,000	)
Net provision for federal income tax	$	0		$	0

The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of September 30, 2013 and December 31, 2012:

	2013			2012
Deferred tax asset attributable to:
Net operating loss carryover	$	4,618,000		$	4,706,000
Valuation allowance		(4,618,000	)		(4,706,000	)
Net deferred tax asset	$	0		$	0

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $13,583,000 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

CONTINGENT LIABILITY

9 Months Ended

Sep. 30, 2013

CONTINGENT LIABILITY

On January 14, 2013, the Company hired a new CEO. The employment agreement required annual compensation of $175,000 that was to be accrued and deferred until at least January 1, 2014. Additionally, the agreement required the issuance of 2,000,000 options with an exercise price of $1.00 for a term of five years. The options were not exercisable until at least January 1, 2014, and were only exercisable after reaching certain financial terms and conditions. Due to these restrictions, no accrual was made for the issuance of these options.

On September 20, 2013, the Company entered into a separation agreement with the CEO. As part of the terms of the separation agreement, the accrued compensation up to the date of separation was paid and the options were terminated. Also as part of the agreement, the Company will be involved with the former CEO in a limited role as a consultant for one year to assist in various initiatives and in transition of various ongoing projects for 500,000 shares of company stock. Half of the value of the shares will be expensed immediately, with the other half expensed over the one year life of the agreement. 7.69% of the second half of the stock value has been expensed at September 30, 2013, with the remainder to be expensed as services are rendered over the remaining life of the agreement. The unamortized balance has been recorded as Deferred Stock Compensation in the equity section of the balance sheet.

OPERATING EXPENSES

9 Months Ended

Sep. 30, 2013

OPERATING EXPENSES

Operating expenses consisted of the following for the three and nine months ended September 30, 2013 and 2012, respectively:

	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Advertising	$	23,207	$	1,167	$	30,372	$	45,088
Professional fees		151,610		83,235		275,004		186,188
Consulting		25,657		0		65,786		7,835
Salaries, wages and benefits		344,979		299,286		1,040,238		900,751
Rent		15,148		15,148		45,444		47,214
Depreciation and amortization		48,225		46,735		144,562		140,087
Stock-based compensation		281,925		29,857		310,823		227,922
Revenue share expense		376,831		20,669		614,234		28,804
General and administrative		94,753		63,208		360,010		197,368
Total Operating Expenses	$	1,362,335	$	559,305	$	2,886,473	$	1,781,257

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2013
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2013 through the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2013
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Form 10-K filed with the SEC as of and for the year ended December 31, 2012. In the opinion of management, all adjustments necessary for the financial statements to be not misleading for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.
Accounting Basis	Accounting Basis The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a December 31 fiscal year end.
Principles of Consolidation	Principles of Consolidation The financial statements reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation (a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of cash, accounts receivable, prepaid expenses, patent rights, web development costs, accounts payable, accounts payable – related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term nature. The fair value of long-term debt, which approximates its carrying value, is based on current rates at which the Company could borrow funds with similar remaining maturities.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Bad debt expense was $0 for the nine months ended September 30, 2013 and 2012, respectively. The allowance for doubtful accounts was $0 as of September 30, 2013 and December 31, 2012, respectively.
Property and Equipment	Property and Equipment The capital assets are being depreciated over their estimated useful lives, three to seven years using the straight-line method of depreciation for book purposes.
Revenue Recognition	Revenue Recognition All revenue is recognized when it is earned. Revenues are generated either through the Company’s website activities, in which we earn revenue from advertising and lead generation activities, or from our SampleMD activities, which include offering setup within the systems and our offers, coupons, and vouchers that enable our customers to save money on medical products and services. The Company’s processes are monitored by third parties who collect revenues from clients on a per activity basis and report and forward the revenue to the Company’s account.
Research and Development	Research and Development The Company’s key members are part of a continual research development team and monitor new technologies, trends, services and partnerships that can provide the Company with additional services, value to healthcare and pharmaceutical industries and to the patients it serves. The Company seeks to educate team members through understanding of all market dynamics that have the potential to affect the business both short term and longer term. The primary goal is to help patients better afford and access the medicines their doctor prescribes, as well as other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission through technology, better user experiences and new ways to engage industries to provide new support for patients needing their products. The Company is always seeking new services and solutions to offer. At this time, the three current platforms provide robust opportunities and growth during the next five years.
Income Taxes	Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Concentration of Credit Risks	Concentration of Credit Risks The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the depreciable lives of such assets and the allowance for doubtful accounts receivable. Actual results could differ from these estimates.
Earnings Per Common and Common Equivalent Share	Earnings Per Common and Common Equivalent Share The computation of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the average market price per share during the year. Options, warrants and convertible preferred stock which are common stock equivalents are included in the per share calculation for the three and nine months ended September 30, 2013. They have not been included in the diluted earnings per share calculation for the three and nine months ended September 30, 2012 since their effect is anti-dilutive.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

PREPAID EXPENSES (Tables)

9 Months Ended

Sep. 30, 2013

Schedule of Prepaid Expenses

	2013		2012
Insurance	$	6,653	$	6,437
Rent		5,049		5,049
Consulting		14,634		31,672
Legal		0		25,000
Total prepaid expenses	$	26,336	$	68,158

PROPERTY AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2013

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

	2013			2012
Computer equipment	$	22,360		$	22,360
Furniture and fixtures		11,088			11,088
Subtotal		33,448			33,448
Accumulated depreciation		(16,984	)		(12,763	)
Property and equipment, net	$	16,464		$	20,685

WEB DEVELOPMENT COSTS (Tables)

9 Months Ended

Sep. 30, 2013

Schedule of Web Development Costs

	2013			2012
OptimizeRx web development	$	154,133		$	154,133
SampleMD web development		602,517			602,517
SampleMD 2.0		62,280			0
Subtotal, web development costs		818,930			756,650
Accumulated amortization		(408,069	)		(310,352	)
Impairment		(59,083	)		(59,083	)
Web development costs, net	$	351,778		$	387,215

PATENT RIGHTS AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Patent and Intangible Assets

	2013			2012
Patent rights and intangible assets	$	930,000		$	930,000
Patent defense costs		38,278			0
Accumulated amortization		(179,388	)		(136,764	)
Patent rights and intangible assets, net	$	788,890		$	793,236

ACCRUED EXPENSES (Tables)

9 Months Ended

Sep. 30, 2013

Payables and Accruals [Abstract]

Schedule of Accured Expenses

	2013		2012
Accrued compensation	$	0	$	0
Accrued audit fees		0		6,000
Total accrued expenses	$	0	$	6,000

STOCK OPTIONS AND WARRANTS (Tables)

9 Months Ended

Sep. 30, 2013

Schedule of Stock Options

	Number of Options			Weighted average exercise price
Outstanding, January 1, 2012		405,000		$	1.01
Granted - 2012		75,000			1.17
Exercised - 2012		0			0
Expired - 2012		(455,000	)		(.98	)
Balance, December 31, 2012		25,000			1.58
Granted - 2013		0			0
Exercised - 2013		0			0
Expired - 2013		0			0
Balance, September 30, 2013		25,000		$	1.58

Schedule of Warrants

	Number of Warrants			Weighted average exercise price
Outstanding, January 1, 2012		14,344,434		$	2.41
Granted - 2012		0			0
Exercised - 2012		0			0
Expired - 2012		0			0
Balance, December 31, 2012		14,344,434			2.41
Granted - 2013		0			0
Exercised - 2013		0			0
Expired - 2013		(672,000	)		(2.59	)
Balance, September 30, 2013		13,672,434		$	2.44

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

OPERATING LEASES (Tables)

9 Months Ended

Sep. 30, 2013

Leases [Abstract]

Schedule of Rent Expense

Year ended December 31, 2013	$	60,591
2014		55,542
2015		0
Total lease commitment	$	116,133

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2013

Income Tax Disclosure [Abstract]

Federal Income Tax

	2013			2012
Federal income tax (expense) benefit attributable to:
Current operations	$	(88,000	)	$	102,000
Valuation allowance		88,000			(102,000	)
Net provision for federal income tax	$	0		$	0

Deferred Tax Asset

	2013			2012
Deferred tax asset attributable to:
Net operating loss carryover	$	4,618,000		$	4,706,000
Valuation allowance		(4,618,000	)		(4,706,000	)
Net deferred tax asset	$	0		$	0

OPERATING EXPENSES (Tables)

9 Months Ended

Sep. 30, 2013

Schedule of Operating Expenses

	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Advertising	$	23,207	$	1,167	$	30,372	$	45,088
Professional fees		151,610		83,235		275,004		186,188
Consulting		25,657		0		65,786		7,835
Salaries, wages and benefits		344,979		299,286		1,040,238		900,751
Rent		15,148		15,148		45,444		47,214
Depreciation and amortization		48,225		46,735		144,562		140,087
Stock-based compensation		281,925		29,857		310,823		227,922
Revenue share expense		376,831		20,669		614,234		28,804
General and administrative		94,753		63,208		360,010		197,368
Total Operating Expenses	$	1,362,335	$	559,305	$	2,886,473	$	1,781,257

NATURE OF BUSINESS (Details Narrative) - shares	9 Months Ended
NATURE OF BUSINESS (Details Narrative) - shares	Sep. 30, 2013	Apr. 18, 2008
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Organization	Jan. 31, 2006
Date of Incorporation	Oct. 22, 2007
Capital stock of OptimizeRx Corporation exchanged for common stock of RFID, Ltd		1,256,958
Ownership of outstanding capital stock of RFID, Ltd.		100.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Accounting Policies [Abstract]
Fiscal Year End	--12-31
Bad Debt Expense	$ 0	$ 0
Allowance for doubtful accounts	$ 0		$ 0
Capital Assets Useful Life, Minimum	3 years
Capital Assets Useful Life, Maximum	7 years

PREPAID EXPENSES - Schedule of Prepaid Expenses (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Insurance	$ 6,653	$ 6,437
Rent	5,049	5,049
Consulting	14,634	31,672
Legal	0	25,000
Total prepaid expenses	$ 26,336	$ 68,158

PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Computer equipment	$ 22,360	$ 22,360
Furniture and fixtures	11,088	11,088
Subtotal	33,448	33,448
Accumulated depreciation	(16,984)	(12,763)
Property and equipment, net	$ 16,464	$ 20,685

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Abstract]
Depreciation	$ 1,407	$ 1,382	$ 4,221	$ 4,094

WEB DEVELOPMENT COSTS - Schedule of Web Development Costs (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Notes to Financial Statements
OptimizeRx web development	$ 154,133	$ 154,133
SampleMD web development	602,517	602,517
SampleMD 2.0	62,280	0
Subtotal, web development costs	818,930	756,650
Accumulated amortization	(408,069)	(310,352)
Impairment	(59,083)	(59,083)
Web development costs, net	$ 351,778	$ 387,215

WEB DEVELOPMENT COSTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
WEB DEVELOPMENT COSTS (Details Narrative) - USD ($)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Notes to Financial Statements
Useful Life of Website			5 years
SampleMD 2.0	$ 62,280		$ 62,280		$ 0
Unamortized Debt Issuance Expense	(59,083)		(59,083)		$ (59,083)
Amortization Expense of Website	$ 32,572	$ 31,677	$ 97,717	$ 94,964

PATENT RIGHTS AND INTANGIBLE ASSETS - Schedule of Patent and Intangible Assets (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Patent rights and intangible assets	$ 930,000	$ 930,000
Patent defense costs	38,278	0
Accumulated amortization	(179,388)	(136,764)
Patent rights and intangible assets, net	$ 788,890	$ 793,236

PATENT RIGHTS AND INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Apr. 26, 2010
Goodwill and Intangible Assets Disclosure [Abstract]
Common stock shares granted to acquire exclusive patent rights					300,000
Options granted to acquire exclusive patent rights					200,000
Options granted to acquire exclusive patent rights, value					$ 360,000
Common stock shares granted to acquire exclusive patent rights, value					$ 570,000
Useful life of Patent			17 years
Amortization Expense of Patent	$ 14,246	$ 13,676	$ 42,624	$ 41,029

ACCRUED EXPENSES - Schedule of Accured Expenses (Details) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]
Accrued compensation	$ 0	$ 0
Accrued audit fees	0	6,000
Total accrued expenses	$ 0	$ 6,000

ACCRUED EXPENSES (Details Narrative)	Jan. 14, 2013 USD ($) shares
Payables and Accruals [Abstract]
Annual Compensation for CEO \| $	$ 175,000
Issuance of stock options to CEO, shares	2,000,000
Issuance of stock options to CEO, par value	1.00
Term of options agreement	5 years
Exercisable date	Jan. 01, 2014

DEFERRED REVENUE (Details Narrative) - USD ($)	Sep. 30, 2013	Dec. 31, 2012
Revenue Recognition [Abstract]
Deferred revenue	$ 13,272	$ 49,252

RELATED PARTY TRANSACTIONS (Details Narrative)	Dec. 31, 2012 USD ($) shares
Related Party Transactions [Abstract]
Share Based Compensation Arrangement of Stock Options Issued \| shares	300,000
Common Stock Issued For Purchase Of Patent \| shares	200,000
Share Based Compensation Arrangement of Stock Options Value \| $	$ 360,000
Common Stock Value On Grant Date \| $	$ 570,000

COMMON STOCK (Details Narrative) - USD ($)	Jan. 02, 2014	Sep. 30, 2013	Sep. 20, 2013	Jun. 01, 2013	Dec. 31, 2012	Jul. 12, 2012	Jun. 01, 2012
Common Stock Shares Authorized		500,000,000			500,000,000
Common Stock Par Value Per Share		$ 0.001			$ 0.001
Common Stock Shares Issued		14,752,496			14,232,496
Shares Issued, value		$ 14,752			$ 14,232
Deferred stock compensation		$ (233,077)			$ 0
North Coast Advisors
Shares Issued				20,000		40,000	40,000
Shares Issued, per share value				$ 1.945		$ 1.12
Term of Agreement				P2Y			P2Y
Separation Agreement
Shares Issued	250,000		250,000
Shares Issued, value			$ 505,000
Deferred stock compensation			$ (233,077)

PREFERRED STOCK (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
PREFERRED STOCK (Details Narrative) - USD ($)	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2008	Sep. 30, 2013	Sep. 30, 2012	Feb. 29, 2012	Sep. 21, 2011	Mar. 25, 2011	Nov. 16, 2010	May 12, 2010
Preferred Stock Series A Stock Share Issued For Proceeds			35
Preferred Stock Series A Value			$ 3,500,000
Preferred Stock Series A Stock Issuance Expense			515,000
Preferred Stock Series A Stock Net Proceeds			$ 2,985,000
Convertible Preferred Stock Series A Shares Issued Upon Conversion			3,500,000
Preferred Stock Series A Stock Dividend Rate Percentage			10.00%
Common Stock Warrants Issued For Purchase	1,000,000	3,000,000	6,000,000
Common Stock Warrants Exercise Price	3.00	3.00	2.00
Common Stock Warrants Expiration	7 years	7 years	7 years
Common Stock Shares Issued For Dividend Payment							156,306	176,768	173,922	236,598
Preferred Stock Series B Shares Issued For Proceeds	15	15
Preferred Stock Series B Value	$ 1,500,000	$ 1,500,000
Convertible Preferred Stock Series B Shares Issued Upon Conversion	1,000,000	1,000,000
Preferred Stock Series B Stock Dividend Rate Percentage	10.00%	10.00%
Preferred Stock Series B Stock Issuance Expense		$ 350,000
Preferred Stock Series B Stock Net Proceeds		$ 1,150,000
Common Stock Warrants Issued		3,000,000
Preferred Stock Value On Grant Date	$ 855,460	$ 341,100
Common Stock Warrant Value On Grant Date	$ 644,540	$ 1,158,900
Common Stock Shares Issued For Dividend Payment For Series B							66,988	75,758
Series A
Undeclared dividends				$ 700,000	$ 350,000	$ 350,000
Series B
Undeclared dividends				$ 300,000	$ 150,000	$ 150,000

STOCK OPTIONS AND WARRANTS - Schedule of Stock Options (Details)	12 Months Ended
	Dec. 31, 2012 shares
Notes to Financial Statements
Beginning Balance, number of shares	405,000
Beginning Balance, weighted average exercise price	1.01
Options granted, number of shares	75,000
Options granted, weighted average exercise price	1.17
Options exercised, number of shares	0
Options exercised, weighted average exercise price	0
Options expired, number of shares	(455,000)
Options expired, weighted average exercise price	(0.98)
Ending Balance, number of shares	25,000
Ending Balance, weighted average exercise price	1.58

STOCK OPTIONS AND WARRANTS - Schedule of Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Notes to Financial Statements
Beginning Balance, number of shares	14,344,434	14,344,434
Beginning Balance, weighted average exercise price	$ 2.41	$ 2.41
Warrants granted, number of shares	0	0
Warrants granted, weighted average exercise price	$ 0	$ 0
Warrants exercised, number of shares	0	0
Warrants exercised, weighted average exercise price	$ 0	$ 0
Warrants expired, number of shares	(672,000)	0
Warrants expired, weighted average exercise price	$ (2.59)	$ 0
Ending Balance, number of shares	13,672,434	14,344,434
Ending Balance, weighted average exercise price	$ 2.44	$ 2.41

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share Based Compensation Expense	$ 281,925	$ 29,857	$ 310,823	$ 227,922
Two Employees Stock Options
Share Based Compensation Expense				14,459
Individual Stock Options
Share Based Compensation Expense				$ 75,117
Non-Employee Stock Options
Share Based Compensation Expense			$ 30,006

Schedule of Rent Expense (Details) - USD ($)	12 Months Ended
Schedule of Rent Expense (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Leases [Abstract]
Minimum Annual Lease Amount	$ 0	$ 55,542	$ 60,591
Total 3 year Lease Commitment			$ 116,133

OPERATING LEASES (Details Narrative)	9 Months Ended
OPERATING LEASES (Details Narrative)	Sep. 30, 2013 USD ($)
Leases [Abstract]
Monthly Rent Due	$ 5,000
Term Of Lease	3 years
Monthly Rent Option	$ 5,200

The increases or decreases in lease payments that result from changes occurring after the inception of the lease in the factors (other than the passage of time) on which lease payments are based, except that any escalation of minimum lease payments relating to increases in construction or acquisition cost of the leased property or for increases in some measure of cost or value during the construction or preconstruction period, are excluded from contingent rentals. Contingent rentals also may include amounts for which the triggering events have not yet occurred or the specified targets for which have not yet been achieved (such as sales based percentage rent), but which events are considered probable of occurring or which specified targets are considered probable of being achieved.